METOPROLOL SUCCINATE
BETA-BLOCKERS (SYSTEMIC) · HYPERTENSION ·+2
NORTHSTAR RX LL
Drug class
Beta-Blockers (Systemic)
Beta-blockers (systemic) are a therapeutic drug class comprising orally or parenterally administered beta-adrenergic receptor antagonists that competitively inhibit endogenous catecholamines throughout the body. Read more about Beta-Blockers (Systemic)
386 drugs in this class 143 manufacturers
Drugs in Beta-Blockers (Systemic)
METOPROLOL SUCCINATE
BETA-BLOCKERS (SYSTEMIC) · HYPERTENSION ·+2
ZYDUS PHARMACEU
SOTALOL (sotalol HCl)
ANTIARRHYTHMIC - CLASS III · LIFE-THREATENING VENTRICULAR TACHYCARDIA ·+2
GSK Consumer Healthcare
ESMOLOL HCL-SODIUM CHLORIDE (esmolol HCl in sodium chloride, iso-osmotic)
BETA-BLOCKERS (SYSTEMIC) · PERIOPERATIVE HYPERTENSION ·+3
MYLAN INSTITUTI
KAPSPARGO SPRINKLE (metoprolol succinate)
BETA-BLOCKERS (SYSTEMIC) · HYPERTENSION ·+2
OHM/SUN PHARMAC
ATENOLOL-CHLORTHALIDONE (atenolol/chlorthalidone)
DIURETICS · HYPERTENSION
NORTHSTAR RX LL
BISOPROLOL-HYDROCHLOROTHIAZIDE (bisoprolol fumarate/hydrochlorothiazide)
DIURETICS · HYPERTENSION
TEVA USA
METOPROLOL TARTRATE
BETA-BLOCKERS (SYSTEMIC) · ACUTE MYOCARDIAL INFARCTION ·+1
FOSUN PHARMA US
LABETALOL (labetalol HCl)
ALPHA-BLOCKERS · HYPERTENSION
EYWA PHARMA INC
Filter & compare in the drug finder →
Opens the drug finder with Beta-Blockers (Systemic) preselected. Add indication or manufacturer filters there.
Beta-blockers (systemic) are a therapeutic drug class comprising orally or parenterally administered beta-adrenergic receptor antagonists that competitively inhibit endogenous catecholamines throughout the body.
By blocking cardiac beta-1 and peripheral beta-2 receptors, these medications exert negative inotropic and chronotropic effects, slowing the heart rate, decreasing myocardial contractility, and lowering systemic arterial blood pressure.
They are primarily indicated across cardiovascular medicine for the management of hypertension, angina pectoris, cardiac arrhythmias, myocardial infarction, and chronic heart failure with reduced ejection fraction.
Additionally, systemic beta-blockers play key therapeutic roles in non-cardiovascular conditions, including migraine prophylaxis, essential tremor, and the symptomatic management of thyrotoxicosis.
-
fda.gov
Beta-blockers (systemic) are a therapeutic drug class comprising orally or parenterally administered beta-adrenergic receptor antagonists that competitively inhibit endogenous catecholamines throughout the body By blocking cardiac beta-1 and peripheral beta-2 receptors, these medications exert negative inotropic and chronotropic effects, slowing the heart rate, decreasing myocardial contractility, and lowering systemic arterial blood pressure
-
nih.gov
Beta-blockers (systemic) are a therapeutic drug class comprising orally or parenterally administered beta-adrenergic receptor antagonists that competitively inhibit endogenous catecholamines throughout the body
-
nih.gov
By blocking cardiac beta-1 and peripheral beta-2 receptors, these medications exert negative inotropic and chronotropic effects, slowing the heart rate, decreasing myocardial contractility, and lowering systemic arterial blood pressure They are primarily indicated across cardiovascular medicine for the management of hypertension, angina pectoris, cardiac arrhythmias, myocardial infarction, and chronic heart failure with reduced ejection fraction Additionally, systemic beta-blockers play key ther...
-
mayoclinic.org
By blocking cardiac beta-1 and peripheral beta-2 receptors, these medications exert negative inotropic and chronotropic effects, slowing the heart rate, decreasing myocardial contractility, and lowering systemic arterial blood pressure
-
nih.gov
They are primarily indicated across cardiovascular medicine for the management of hypertension, angina pectoris, cardiac arrhythmias, myocardial infarction, and chronic heart failure with reduced ejection fraction
-
clevelandclinic.org
They are primarily indicated across cardiovascular medicine for the management of hypertension, angina pectoris, cardiac arrhythmias, myocardial infarction, and chronic heart failure with reduced ejection fraction Additionally, systemic beta-blockers play key therapeutic roles in non-cardiovascular conditions, including migraine prophylaxis, essential tremor, and the symptomatic management of thyrotoxicosis
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.